Cassava Sciences Board Shake-up: New Director Appointed, One Departs
Ticker: FLNA · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, director-appointment, director-resignation
Related Tickers: SAVA
TL;DR
Cassava Sciences board sees a change: Dr. Kuo out, Dr. Schoen in as of Sept 6.
AI Summary
Cassava Sciences, Inc. announced on September 6, 2024, a change in its board of directors. Specifically, Dr. James M. Kuo has resigned from his position as a director, effective immediately. The company has also appointed Dr. Eric J. Schoen as a new director, effective the same date. Dr. Schoen brings extensive experience in the pharmaceutical industry.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and leadership stability.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Dr. James M. Kuo (person) — Resigned Director
- Dr. Eric J. Schoen (person) — Appointed Director
- September 6, 2024 (date) — Effective date of changes
FAQ
Who resigned from the Cassava Sciences board of directors?
Dr. James M. Kuo resigned from the board of directors of Cassava Sciences, Inc.
When was Dr. James M. Kuo's resignation effective?
Dr. James M. Kuo's resignation was effective September 6, 2024.
Who was appointed to the Cassava Sciences board of directors?
Dr. Eric J. Schoen was appointed to the board of directors of Cassava Sciences, Inc.
When was Dr. Eric J. Schoen's appointment effective?
Dr. Eric J. Schoen's appointment was effective September 6, 2024.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 6, 2024.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 9.4 · Accepted 2024-09-09 08:46:47
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_090924.htm (8-K) — 18KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-005116.txt ( ) — 228KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_090924_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 9, 2024, Cassava issued a press release related to the matters described in Items 5.02 of this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated September 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. a Delaware corporation Date: September 9, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer